Prognostic value of annexin A5-1 C/T polymorphism in a long term follow-up after premature myocardial infarction [2]

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 4, 2007, Pages 862-863

  Roldan V ^a   Marin F ^b   Gonzalez Conejero R ^a   Corral, J ^a   Vicente, Vicente ^a,c  

^a UNIVERSITY OF MURCIA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOCORTIN 5; THYMINE;

ACUTE HEART INFARCTION; ADULT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; INFORMED CONSENT; KAPLAN MEIER METHOD; LETTER; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTPATIENT CARE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; RESTRICTION MAPPING; SURVIVAL RATE; UNIVARIATE ANALYSIS; UNSTABLE ANGINA PECTORIS;

ADULT; ALLELES; ANNEXIN A5; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; TIME FACTORS;

EID: 34147191130     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02419.x     Document Type: Letter

References (16)

1. Thiagarajan P, Tait JF. Binding of annexin V/placental anticoagulant protein I to platelets. J Biol Chem 1990; 265: 17420-3.
2. Tait JF, Gibson D. Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. J Lab Clin Med 1994; 123: 741-8.
3. Andree HA, Stuart MC, Hermens WT, Reutelingsperger CP, Hemker HC, Frederik PM, Willems GM. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992; 267: 17907-12.
4. Ravanat C, Archipoff G, Beretz A, Freund G, Cazenave JP, Freyssinet JM. Use of annexin V to demonstrate the role of phosphatidyl-serine exposure in the maintenance of haemostatic balance by endothelial cells. Biochem J 1992; 282: 7-13.
5. van Heerde WL, de Groot PG, Reutelingsperger CPM. The complexity of the phospholipid binding protein annexin V. Thromb Haemost 1995; 73: 172-9.
6. van Heerde W, Jumilly AL, Lux P, Meyer D, Hamulyak K, Lavergne JM, Reutelingsperger CPM. Mutations in the annexin V gene, a new risk factor for venous thrombosis? Thromb Haemost 1999; S: 537 (abstract 1691).
7. González-Conejero R, Corral J, Roldán V, Martínez C, Marín F, Rivera J, Iniesta JA, Lozano ML, Marco P, Vicente V. A common polymorphism in the Annexin V Kozak sequence (-1 C to T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. Blood 2002; 100: 2081-6.
8. van Heerde WL, Kenis H, Schoormans S, Lap P, Reutelingsperger CP. The -1 C > T mutation in the annexin A5 gene does not affect plasma levels of annexin A5. Blood 2003; 101: 4223-4.
9. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith Jr SC, American College of Cardiology; American Heart Association; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 2004; 44: 671-719.
10. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
11. Ozaki K, Tanaka T. Genome-wide association study to identify SNPs conferring risk of myocardial infarction and their functional analyses. Cell Mol Life Sci 2005; 62: 1804-13.
12. Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: Angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 1995; 26: 654-61.
13. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107: 1117-22.
14. Antithrombotic Triallists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
15. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-32.
16. Williams MJ, Restieaux NJ, Low CJS. Myocardial infarction in young people with normal coronary arteries. Heart 1998; 79: 191-4.